- Clearmind Medicine Inc. (CMND, Financial) to host 'Gazing Through the Crystal Ball' webinar on May 21, 2025.
- Experts to discuss the evolving psychedelic science landscape with a focus on FDA policies.
- Key speakers include Rick Doblin, Robin Carhart-Harris, and Dr. Adi Zuloff-Shani.
Clearmind Medicine Inc. (CMND), a prominent clinical-stage biotech firm, has announced its upcoming live webinar titled "Gazing Through the Crystal Ball." Scheduled for May 21, 2025, at 12:00 PM ET, the event will feature a stellar lineup of experts who will explore the shifting landscape of psychedelic science and business, particularly in the context of changing FDA policies and political climates.
The distinguished panel of speakers includes Rick Doblin, PhD, the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), and Robin Carhart-Harris, PhD, a distinguished professor of neurology and psychiatry at UCSF. Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, will also speak, focusing on the development of CMND-100, the company's innovative treatment for Alcohol Use Disorder (AUD) currently advancing in FDA-approved clinical trials. Mark Haden, VP Business Development for Clearmind and adjunct professor at the University of British Columbia, will lend his insights into drug policy reform.
The discussion will be moderated by Shannon Smadella, a wellness advocate and podcast host recognized for her contributions to raising public awareness in the psychedelic domain. This event represents a significant step for Clearmind as it continues to lead efforts in psychedelic-derived therapeutics.
For those interested in attending, registration is available on Clearmind Medicine's official website. This webinar offers an opportunity for investors and stakeholders to gain in-depth insights into the future of psychedelic sciences and regulatory advances.
Additional information can be obtained by contacting Clearmind at [email protected].
